BSE
MARKET ANALYSIS NEWS CORPORATE INFORMATION CORPORATE ACTIONS OTHER MARKETS
Your Result on : Company News
Aurobindo Pharma Ltd Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
524804
ISIN Demat
INE406A01037
Book Value (Rs)
369.1611632
NSE Symbol
AUROPHARMA
Divident Yield %
0
Market Cap
(Rs In Cr.)
75,951
P/E (TTM)
35.43
EPS (TTM)
36.91
Face Value
(Rs)
1
Date Heading
04-Mar-26 Eugia Pharma Specialities launches Pomalidomide Capsules in US market
04-Mar-26 Aurobindo Pharma launches Pomalidomide capsules in US market
28-Feb-26 Aurobindo Pharma arm receives 4 observations after US FDA inspection
26-Feb-26 Eugia Pharma Specialities receives USFDA approval for Everolimus Table
26-Feb-26 Aurobindo Pharma gains as arm gets USFDA final nod for Everolimus tabl
26-Feb-26 Aurobindo Pharma Ltd spurts 1.16%
14-Feb-26 Aurobindo Pharma consolidated net profit rises 7.62% in the December 2
09-Feb-26 Aurobindo Pharma board considers merger of subsidiaries
09-Feb-26 Board of Aurobindo Pharma approves PPA with Garuda Renewables
09-Feb-26 Aurobindo Pharma board appoints directors
07-Feb-26 USFDA completes audit of Unit III of Eugia Pharma Specialities
31-Jan-26 Aurobindo Pharma to announce Quarterly Result
30-Jan-26 Volumes soar at Aurobindo Pharma Ltd counter
30-Jan-26 Aurobindo Pharma Ltd gains for third straight session
02-Jan-26 Indices edge higher in early trade; breadth strong
Risk Factor   |   Terms & Conditions   |   Privacy Policy   |   Disclaimer   |  Sitemap 
Important Links:   SEBI   |   NSE   |   BSE   |   MCX   |   NCDEX   |   NSDL   |   CDSL  |   FMC
SMS FINANCIAL SERVICES P. LTD -NSE SEBI No. AP1413004363 | BSE SEBI No. AP01091801121968
Ganesh S Shanbhag – AMFI Registered Mutual Fund Distributor. Registration Number – ARN-0988 – Valid Till 01/JUL/ 2027, Date of initial registration: 02/DEC/2004
2017-18 © SMS Financial Services. All rights reserved. Designed, Developed and Maintained by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)